RxDoctor Payments Data

Ileana Fumero

Psychiatry · San Juan, PRNPI 1083828578

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $103,035 of the $127,690 with a category attached, or 80.7%. 11 manufacturers reported payments, led by Johnson & Johnson at 54.3% of the total. Among psychiatry clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$127,690in general payments, 2019–2025

Across 218 payments — averaging $585.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$69K
  • AbbVie$31K
  • E.r. Squibb & Sons, L.L.C.$16K
  • Teva Pharmaceuticals USA, Inc.$10K
  • Janssen Scientific Affairs, LLC$200
  • Sunovion Pharmaceuticals Inc.$169
  • plus $293 from 5 others
$1,038,016in research payments, 2019–2025

Across 303 payments — averaging $3425.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$317K
  • Eli Lilly Export S.A. Puerto Rico Branch$266K
  • Alkermes, Inc.$149K
  • AbbVie$147K
  • Supernus Pharmaceuticals, Inc.$105K
  • E.r. Squibb & Sons, L.L.C.$19K
  • plus $34K from 3 others

What the payments were for

  • Consulting fees$13,44911%
  • Speaking & faculty fees$103,03581%
  • Travel & lodging$5,3554%
  • Food & beverage$5,8535%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$127,690 in reported general payments places this provider in the 95th percentile of 312 psychiatry providers in Puerto Rico.

See all psychiatry providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$92,231
MyrbetriqMirabegron12$5,547
PristiqDesvenlafaxine Succinate11$4,874
Bupropion XlBupropion Hcl74$2,383
Clorazepate Dipotassium38$2,306
Trazodone Hcl130$2,252
Clonazepam238$2,148
Donepezil Hcl130$2,046
Desvenlafaxine Succinate ErDesvenlafaxine Succinate46$1,594
Paroxetine CrParoxetine Hcl18$1,495
Estazolam25$1,436
Memantine Hcl ErMemantine Hcl31$1,432
Sertraline Hcl157$1,382
Rivastigmine13$1,297
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$1,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$31,216$94319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 psychiatry providers in Puerto Rico.

Other psychiatry in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →